TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04107480
Drug: Dopamine Agonists
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treating physician adheres to the treatment protocol in general, but has freedom to choose treatment to his/her ideas how to deliver best care.~Current first line treatment consists of a dopamine agonists: cabergoline (currently the most used), bromocriptine or quinagolide. All dopamine agonists are taken orally, and the dosage may be raised based on its effect. It is usually titrated to achieve a normal or suppressed prolactin level and restoration of the gonadal axis. Dopamine agonist treatment is discontinued after 2 years of treatment, unless a normal prolactin level cannot be achieved. The dopamine agonist is restarted when prolactin levels rise after the medication is discontinued.~In standard care, surgical treatment is reserved for patients who don't tolerate medication, or whose adenoma fails to show a sufficient response. Patients in the control group with an intolerance for dopamine agonists or an insufficient response may be offered surgery as part of standard care.
Study: NCT02212821
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02212821
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: physiological saline
Study: NCT01925300
Drug: Concor 5mg 2T and Crestor 20 mg 1Tab
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00987701
Drug: Ringer's Lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's Lactate 8 ml/kg was given intravenously before or after epidural, spinal or CSEA in cesarean section
Study: NCT00653354
Drug: valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by valdecoxib 20 mg tablet by mouth 1 to 12 hours after the first dose
Study: NCT00653354
Drug: valdecoxib/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
Study: NCT00653354
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
Study: NCT03130452
Drug: Clarithromycin 500mg
Normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 500mg tablet
Study: NCT02241187
Drug: PEGPH20
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03919461
Drug: Propranolol and etodolac
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A perioperative combined drug regimen
Study: NCT02048215
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
Study: NCT03603795
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo concomitant with induction chemotherapy patients with AML
Study: NCT02048215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
Study: NCT01868633
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01437228
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO İNTERVENTİON
Study: NCT03703635
Drug: aggressive medical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100mg once/day during the follow-up period, Clopidogrel 75mg once/day for at least 90 days, Atorvastatin 20-80mg once/day as the situation requires and risk factors management including blood pressure to maintain 130-140/80-90 mmHg and LDL lower than 70 mg/dl or 1.8mmol/L.
Study: NCT00617955
Drug: Aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: compare outcomes of Aprotinin versus Amicar
Study: NCT03445390
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1 g intravenous given at the beginning and end of surgery.
Study: NCT03445390
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match acetaminophen given at the beginning and end of surgery.
Study: NCT00688766
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
Study: NCT02211469
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04197661
Drug: HSK3486
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
Study: NCT04328961
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.
Study: NCT03806582
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intervention with norepinephrine to reach a MAP of 85 mmHg
Study: NCT01723228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01387607
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice daily
Study: NCT03553316
Drug: PK101-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: -(Single) PK101-002
Study: NCT00689481
Drug: U0267 Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
Study: NCT03212963
Drug: Halobetasol Topical Lotion
Normalized name: halobetasol Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halobetasol Lotion 0.05%, applied twice daily in subjects aged 12 to 16 years 11 months with stable plaque psoriasis.
Study: NCT02326142
Drug: OBE001
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBE001 dispersible tablets for a single oral dose a day for up to 7 days.
Study: NCT02326142
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dispersible tablets for a single oral dose a day for up to 7 days.
Study: NCT00649181
Drug: Zaroloxyn® Tablets 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x5mg, single dose fasting
Study: NCT03265093
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection
Study: NCT03865290
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral matched placebo
Study: NCT02871843
Drug: TMZ Maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMZ maintenance at 150-200 mg/m2
Study: NCT03063359
Drug: Intranasal fentanyl + Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of intranasal fentanyl (1.5µg/kg) and Oral placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
Study: NCT00214955
Drug: ORAVESCENT Fentanyl Citrate
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04651959
Drug: AVICOD 200 MG Film Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVICOD is containing 200 mg favipiravir manufactured by Pharma Plant,Turkey.
Study: NCT04651959
Drug: AVIGAN 200 MG Film Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan
Study: NCT02659865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02659865
Drug: LY3039478 original formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02659865
Drug: LY3039478 new formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01285765
Drug: RCHOP21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone-60 mg/m2: D1 D2 D3 D4 D5;Rituximab-375 mg/m2 : D1; Doxorubicin-50 mg/m2 D1;Cyclophosphamide-750 mg/m2:D1 Vincristine-1.4 mg/m2 :D1; G-CSF SC -5 microg/kg/day: D6 to D13
Study: NCT04433013
Drug: Lianhua Qingwen
Approvals — FDA: no, EMA: no, PMDA: no
Description: The LHQW capsules will be administered to trial participants 4 capsules, 3 times a day, after meal
Study: NCT04433013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo capsules will be administered to trial participants 4 capsules, 3 times a day, after meal
Study: NCT00646204
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tabs bid
Study: NCT01188057
Drug: NIRAVAM TM 2 mg orally disintegrating tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Schwarz Pharma Inc. formulated products non-under fasting conditions
Study: NCT02582840
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet. Oral dose
Study: NCT02208791
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00486122
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03789552
Drug: T89 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: T89 capsules (75mg)
Study: NCT03789552
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (0mg)
Study: NCT02356809
Drug: Neovasculgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neovasculgen is an original gene construction that contains supercoiled plasmid DNA (1.2 mg) that encodes pCMV-vegf165 as the active substance. The drug will be supplied to the study centre as a sterile lyophilisate that will be then dissolved in 2 ml of water for injections immediately prior to administration. The drug will be administered intramuscularly (interosseous muscles of hand) at 4-5 injection sites in the dorsal surface of the hand.
Study: NCT02223481
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00235950
Drug: Rosuvastatin or atorvastatin or simvastatin and clopidogrel
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00963768
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A liquid suspension of placebo will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser once or twice daily for 14 days (Day 1 and Days 3 through 16).
Study: NCT01872871
Drug: Topical anaesthetic drop with placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03949075
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be assigned to daily administration of placebo (5-20 mg CaCO3) combined with an 8-week training period.
Study: NCT01806649
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006219
Drug: clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00006219
Drug: prasterone
Normalized name: Prasterone
DrugBank: Prasterone sulfate (DB05804)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00417183
Drug: Arvekap 0.1 mg (Triptorelin, Ipsen, France)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01204866
Drug: Valortim and Selected Components
Normalized name: 1,3-beta-glucan synthase component FKS1
Approvals — FDA: no, EMA: no, PMDA: no
Description: • It is anticipated that up to 4 subjects that received Valortim in a previous study (#0036-08-05) will participate in Stage II of the study; two of these subjects experienced adverse events while being dosed with Valortim. Subjects will each be tested percutaneously with Valortim, polysorbate 80, mannitol, histamine, and saline.~* Only one subject will be skin tested in a single day.~* The appropriate dilution for Valortim, mannitol, and polysorbate 80 will be based on the results from Stage I of this study. As was done in Stage I, Valortim will be filtered through a 0.22 µm syringe filter. Histamine (1 mg/mL) and saline (0.9%) will be used as the positive and negative controls, respectively
Study: NCT01631474
Drug: CB-03-01
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream, applied once a day
Study: NCT01631474
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream, applied once or twice a day
Study: NCT01631474
Drug: CB-03-01
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream, applied twice a day
Study: NCT00958776
Drug: Placebo+SOC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
Study: NCT00062426
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00062426
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00062426
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00263523
Drug: [11C] (-)-RWAY
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02514252
Drug: Fentanyl Sublingual Spray (FSS)
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage 1: First Pain Episode - Single dose of breakthrough opioid given from existing PCA pump equivalent to 10% of their MEDD.~Second Pain Episode - Single dose of FSS equivalent to 16-32% of MEDD. If not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum.~Third Pain Episode (at least 4 hours after second episode) - Participant required 2 breakthrough FSS doses for the last episode of breakthrough pain, or if the effective dose has not been identified, he/she will double the last administered dose. If breakthrough pain not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum).~Stage 2: If FSS successful in hospital, upon discharge, FSS used as first choice of pain medication instead of oral pain medication for pain for up to 4 weeks.
Study: NCT02053727
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00632697
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00261482
Drug: norelgestromin + ethinyl estradiol
Normalized name: ethinyl estradiol / norelgestromin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03314805
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml saline, 3 days via i.v. infusion per chemotherapy cycle
Study: NCT04429022
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1000mg PO x1 prior to surgery (in pre-op) Acetaminophen 1000mg PO q6h x 2 days then 1000mg q6h PRN post op
Study: NCT04429022
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200mg PO q 12h x 7d post op
Study: NCT04429022
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30mg IV once at end of hysterectomy procedure
Study: NCT00333112
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03756220
Drug: Combination therapy of vitamin C and thiamine
Normalized name: combinations of levothyroxine and liothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (50 mg/kg up to 3 g, every 12 hours) and thiamine (200 mg every 12 hours) intravenously administered mixed in 50 mL solution bags of normal saline for 2 days
Study: NCT01213030
Drug: [F-18] FMISO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mCi \[F18\] HX4 and 10 mCi \[F-18\] FMISO within 7 days of each other regardless of sequence
Study: NCT01213030
Drug: [F-18] HX4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mCi \[F18\] HX4 and 10 mCi \[F-18\] FMISO within 7 days of each other regardless of sequence
Study: NCT00454649
Drug: Axitinib + Capecitabine (Cohort 6)
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1000 mg/m\^2) orally BID from Day 1 to Day 14 of each cycle.
Study: NCT00454649
Drug: Axitinib + Capecitabine (Cohort 7)
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1250 mg/m\^2) orally BID from Day 1 to Day 14 of each cycle.
Study: NCT02170909
Drug: BIBR 1048 MS high dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03985007
Drug: CDIAG regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, decitabine 20mg/m2 intravenously daily for 5 days (d1-d5) and IAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 4-17; idarubicin, 5mg intravenously every other day on days 4, 6, 8, 10, 12, 14; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily on days 3-17.
Study: NCT02552862
Drug: Vivomixx®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vivomixx® is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) and lactobacilli (L. paracasei DSM 24733, L. acidophilus DSM 24735, L. delbrueckii subsp bulgaricus DSM 24734, L. plantarum DSM 24730). The active agent will be supplied as a 4.4g sachet at a dose of 450 billion live bacteria per sachet with maltose and silicon dioxide as excipients.
Study: NCT02552862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
Study: NCT01069055
Drug: Intravenous lornoxicam
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the surgery.
Study: NCT01069055
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the surgery.
Study: NCT01744314
Drug: Indomethacin and Pantoprazole
Normalized name: pantoprazole, amoxicillin and clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03948685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03984656
Drug: serratus plane block treatment
Normalized name: Fucus serratus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Serratus plane block is located at the level of the 5th rib, on the midaxillary line, on the drainage side, ultrasound guided. The block is performed with a 70 mm needle in the ultrasound plane, and the needle is directed postero-inferior, after visualization of the structures from the surface to the depth: dorsal muscle~* anterior serratus large muscle (serratus anterior)~* intercostal muscle~* 4th and 5th ribs~* pleura A single injection of 30 mL of Ropivacaine 4.75 mg / mL is performed around the Serratus muscle.~An intravenous injection of 8 mg of Dexamethasone is added to prolong the duration of the block.
Study: NCT03551548
Drug: Spironolactone 25mg
Normalized name: SPIRONOLACTONE 25MG TAB
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg oral spironolactone once daily on top of standard therapy, started 14 ± 4 days before cardiac surgery and continued during 30 days after surgery.
Study: NCT00758589
Drug: AZD1981
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet, 50 mg twice daily
Study: NCT00758589
Drug: AZD1981
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet, 400 mg twice daily
Study: NCT00758589
Drug: AZD1981
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet, 1000 mg twice daily
Study: NCT00758589
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03551548
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo once daily on top of standard therapy, started 14 ± 4 days before cardiac surgery and continued during 30 days after surgery.
Study: NCT01825941
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01229579
Drug: Zinc Sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2.5 ml Zinc supplement syrup daily containing 10 mg of elemental zinc from day 14 to 18 weeks of age.
Study: NCT01547091
Drug: Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: -Patients will be treated by conventional drugs (DMARDS) for alleviating disease.
Study: NCT03289169
Drug: MEDITOXIN®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20U of Meditoxin® is injected to two places on the corrugators muscle for each eye and one place on the procerus muscle, total of 5 sites.
Study: NCT01035346
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of a novel ibuprofen formulation (equal to 400mg ibuprofen)